Introduction
Hematopoietic SCT (HSCT) is standard treatment for a variety of hematological disorders, including aplastic anaemia, leukaemia, lymphoma, multiple myeloma and certain solid tumours. While offering the potential for cure, a major limitation of HSCT remains the increased risk of organ toxicity and transplant-related mortality, particularly in the first 100 days after transplant. Allogeneic HSCT involves greater risk of toxicity in comparison with autologous transplantation due in part to the direct organ toxicity from the more intensive conditioning chemotherapy and/or radiation treatment and related to specific complications, such as hepatic veno-occlusive disease, GVHD and opportunistic infections that often require the involvement of intensive care units (ICUs). [1] [2] [3] Published studies describe ICU admission rates ranging from 10 to 40%, [3] [4] [5] although one recent study regarding autologous HSCT patients reported a 3.3% rate of ICU admission. 6 Although survival rates of HSCT recipients admitted to ICU have gradually improved over the past two decades, 7 long-term survival remains low and fewer than 10% of mechanically ventilated patients survive beyond 12 months post-ICU admission in several series. [8] [9] [10] Timely transfer of critically ill patients to ICU may not always occur for a variety of logistical and practical reasons, increasing the risk of further physiological deterioration and worsened patient outcomes. [11] [12] [13] With this in mind the concept of 'critical care outreach' was adopted in Australia in the 1990s 14 and may reduce cardiac arrests in hospital wards. [15] [16] [17] Critical care outreach (CCO) programs typically involve a team of physicians, nurses and/or respiratory therapists with the flexibility and resources to perform rapid assessments and consultations on critically ill patients admitted to medical, surgical or other hospital wards. Its early acceptance and widespread adoption encouraged the establishment of a similar program at our institution in January 2005, referred to as the Rapid Assessment of Critical Events (RACE). Initial experience has revealed a decrease in cardiac arrests and overall ICU admissions 18 and may be used to detect preventable adverse events. 19 The mandate of RACE at our hospital remains two-fold: (1) earlier recognition of deteriorating patients based on detected abnormalities in vital signs, and (2) rapid response by a designated team possessing the required expertise and resources.
Although there is conflicting evidence regarding the utility of CCO programs, several studies have documented benefits, such as decreased rates of cardiac arrest, fewer unanticipated ICU admissions, reduced post-operative complications and reduced mortality. [15] [16] [17] [20] [21] [22] [23] [24] [25] [26] [27] Previous studies, however, have not addressed the role of CCO in patients undergoing HSCT who remain at high risk of clinical deterioration. The objective of this study was to determine the impact of RACE on clinically relevant outcomes of adult patients undergoing HSCT.
Materials and methods

Study design and patients
To determine the impact of the RACE service in our institution, we performed a retrospective comparative analysis of patients who had received HSCT before and after the program's introduction. RACE was introduced on January 1, 2005 at our institution. Patients transplanted between January 1, 2000 and December 31, 2004 were included in the pre-RACE cohort and patients transplanted between January 1, 2005 and December 31, 2007 were included in the post-RACE cohort. All patients in the study were 18 years of age or older and provided written informed consent for the anonymous use of medical information for research purposes (Ottawa Hospital Research Ethics Board protocol #2004489-01H).
Data regarding patient and transplant variables were exported from the Blood and Marrow Transplant Program database. Hospital medical records were reviewed in detail of patients admitted to ICU. For patients with multiple ICU admissions in the same hospitalization, only the first admission was included in the analysis.
Rapid assessment of critical events team
The RACE service is comprised of a critical care nurse, respiratory therapist and medical doctor. A staff intensivist is available during day-time hours (0800-1700) and a senior resident or fellow is available at night and on weekends with the support of a staff intensivist. A resuscitation cart is present at all RACE consults and is equipped with a full range of medications and tools to facilitate ICU-level care anywhere in the hospital (for example, vasoactive medications, intravenous fluids, equipment for electrocardiographic and repeated blood pressure monitoring, and equipment for invasive and non-invasive ventilation). RACE calls are initiated by any health care provider using well-established criteria (see Box 1) . The RACE team responds to all urgent ward-based calls and provides follow-up care to all patients previously admitted to ICU for at least two days after discharge from ICU.
Diagnostic criteria
Sepsis was defined using the American College of Chest Physicians/Society of Critical Care Medicine guidelines. 28 Criteria for dysfunctional organs and systems (cardiovascular, pulmonary, renal, hematological and metabolic) were based on previously reported definitions (see Box 2) . 28, 29 Absolute neutropenia was considered to be a neutrophil count less than 500 cells/mL. Acute respiratory distress syndrome was defined according to the American-European Consensus Conference. 30 Both vasopressors and inotropes were considered as vasoactive medications.
Outcome measures
The primary outcome was non-relapse mortality before day 100 after transplant. Secondary end points included incidence and duration of ICU admission, incidence and duration of mechanical ventilation, use and duration of vasoactive medications (that is, vasopressors and/or inotropes), the number of failing organs at time of ICU admission and Acute Physiology and Chronic Health Evaluation II (APACHE II) score at ICU admission APACHE II is a validated and widely used prognostic scoring system that predicts survival of patients admitted to intensive care units based on acute physiological and laboratory parameters collected within the first 24 h of ICU admission in addition to several chronic health indicators. 31 
Statistical analysis
Baseline characteristics were compared using Student's t-test or the Wilcoxon rank-sum test for continuous Increased concern about patient, needs assistance, failure to respond to therapy
Box 2
Criteria for dysfunctional organs or systems 1) Cardiovascular: arterial systolic blood pressure p90 mm Hg or mean arterial pressurep70 mm Hg for at least 1 h despite adequate fluid resuscitation, adequate intravascular volume status or the use of vasopressors in an attempt to maintain a systolic blood pressure X90 mm Hg or a mean arterial pressure X70 mm Hg 2) Kidney: urine output o0.5 c.c./kg of body weight/h for 1 h, despite adequate fluid resuscitation 3) Respiratory: the ratio of PaO 2 to FiO 2 had to be p250 in the presence of other dysfunctional organs/systems or p200 if the lung was the only dysfunctional organ 4) Haematological: platelet count o80 000/mm 3 or to have decreased by 50% in the 3 days preceding enrolment 5) Metabolic: pHp7.30 or a base deficit X5 mmol/L in association with a plasma lactate level that was 41.5 times the upper limit of the normal value for the reporting laboratory Univariate and multivariate logistic regression were used to examine factors associated with ICU survival. Regression analyses were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Model parameters were estimated using the method of maximum likelihood and nested models were compared using the À2 log likelihood test.
Results
Cohort of patients undergoing HSCT
A total of 814 transplants were performed at our institution during the study period, including 524 autologous and 290 allogeneic recipients (Table 1) . Major demographic and clinical characteristics between the pre-and post-RACE cohorts were similar with respect to gender, underlying diagnosis, conditioning regimen, type of transplant and source of stem cells. The average age of the pre-RACE cohort, however, was statistically lower than the post-RACE cohort (46.0 ± 13.7 vs 48.8 ± 12.5, P ¼ 0.004) and the pre-RACE group received greater numbers of CD34 þ stem cells in peripheral blood stem cell products (7.6±6.4 vs 6.5±5.6 Â 10 6 CD34 þ cells/kg, P ¼ 0.015).
Regarding our primary outcome, non-relapse mortality by day 100 after transplant was not statistically different between the pre-RACE and post-RACE cohorts (26 patients (10.2%) vs 53 patients (8.8%), P ¼ 0.62). With regard to patients undergoing allogeneic transplant, nonrelapse mortality was similar before and after the introduction of RACE (22.5 vs 18.2%, P ¼ 0.25). A total of 64 patients (12.3%) were admitted to the ICU in the pre-RACE group compared with 42 patients (14.3%) in the post-RACE cohort (P ¼ 0.44).
Cohort of patients admitted to ICU
Characteristics of the pre-RACE and post-RACE groups admitted to ICU are presented in Table 2 . The most frequent reason for ICU transfer in both groups was sepsis, accounting for 48 patients (75%) in the pre-RACE group and 30 patients (71%, P ¼ 0.25) in the post-RACE cohort. All baseline characteristics of patients in the pre-RACE and post-RACE cohorts were similar except for a reduced incidence of cardiovascular failure in patients admitted to ICU in the post-RACE group (23.8 vs 43.8%, P ¼ 0.04) (see Table 2 ).
With regard to patients requiring ICU admission, statistically significant differences in non-relapse mortality by day 100 after transplant were not detected and the requirement for and duration of invasive mechanical ventilation, the use and duration of vasoactive medications, duration of ICU admission and ICU or hospital survival rates were not different between the two groups ( Table 3 ). The number of failed organs at time of admission was lower in patients having access to the RACE team compared with patients in the pre-RACE cohort (1.9 ± 0.8 vs 2.3 ± 1.0, P ¼ 0.04) ( Table 3) .
With respect to the involvement of the CCO team during the post-RACE period, detailed data were reviewed on 28 patients admitted to ICU between 2005 and 2007 and an additional 15 patients who were seen by RACE but not transferred to the ICU. On average, patients were seen 1.6 times before transfer to ICU. CCO also provided follow-up visits after discharge from the ICU. On average patients transferred to the ICU were seen a total of 3.0±1.7 times. In contrast, patients seen by RACE but not transferred to the ICU were seen 4.6 ± 3.1 (P ¼ 0.25) times by the CCO team. 
Predictors of survival in patients admitted to ICU
Cohort of patients undergoing allogeneic HSCT
Due to their increased risk of toxicity as compared to autologous recipients, the impact of RACE on patients undergoing allogeneic stem cell transplant was examined separately. In addition to similar rates of non-relapse Critical care outreach in BMT O Hayani et al mortality at day 100 after transplant in both the pre-and post-RACE cohorts, ICU admission rates for patients undergoing allogeneic transplant were not different in the two cohorts (35 (19.8%) pre-RACE and 26 (23.4%) post-RACE, P ¼ 0.46). The most common reason for transfer to the ICU in both groups was sepsis (57.1 vs 46.2%, P ¼ 0.44). Gender, age and APACHE-II scores during ICU diagnosis were similar in the two cohorts. Patients undergoing allogeneic transplantation, however, were at increased risk of ICU transfer compared with autologous transplant recipients in both the pre-RACE (19.0 vs 8.5%, Po0.05) and in the post-RACE period (23.4 vs 8.7%, Po0.05). Among allogeneic recipients admitted to the ICU, 25 (71%) in the pre-RACE cohort suffered non-relapse death by day 100 after transplant compared to 14 (54%) in the post-RACE cohort (P ¼ 0.19). The number of failed organs at time of ICU admission in the pre-RACE group compared with the post-RACE cohort was 2.3±1.0 compared with 2.0 ± 0.9 (P ¼ 0.26); however, there was a trend towards reduced mean days of invasive mechanical ventilation (10.4±13.2 vs 6.0±5.4 days, P ¼ 0.12) in the post-RACE group. The use and duration of vasoactive medications, discharge rate to the ward and discharge rate out-of-hospital were not different between the two groups.
Discussion
The impact of CCO on patients undergoing HSCT was addressed in our study by comparing patient outcomes before and after the introduction of a RACE team. Although no significant difference was noted in rates of non-relapse mortality at day 100 after transplant, the data suggests that critically ill patients may experience earlier stabilization by the RACE team, highlighted by a significant reduction in the number of failed organ systems at time of ICU admission and reduced incidence of cardiovascular failure. In the subgroup of patients undergoing allogeneic transplantation, there was a trend towards reduced non-relapse mortality and reduced days of invasive mechanical ventilation in the post-RACE group. Whereas CCO has shown potential benefit in various patient populations, our report provides unique insight regarding the impact on patients undergoing stem cell transplantation.
Non-relapse mortality of HSCT recipients admitted to the ICU was particularly elevated and did not significantly change after the introduction of the RACE team. Although the overall mortality of HSCT recipients admitted to ICU remains high, our results are consistent with recent reports, which suggest a gradual improvement when compared with results from earlier periods. [3] [4] [5] [6] [7] [8] [9] [10] Progress in the management of sepsis and new approaches to initiating and weaning patients from mechanical ventilation are a few examples of interventions that may have contributed to the overall trend towards more rapid physiological stabilization of patients admitted to ICU.
Knowledge of important prognostic factors that influence patient outcomes for those admitted to ICU may facilitate improvements in the care of critically ill HSCT patients. In this study, we did not observe an association between increasing age and ICU mortality. This may be particular to HSCT, as patients undergoing transplant have been well selected using pre-transplant screening for organ dysfunction and overall fitness. Univariable analysis revealed the presence of respiratory or cardiovascular failure, increased APACHE II score and elevated serum lactate as being significantly associated with ICU mortality, results in keeping with recent published studies. 4, 5, 6, 8, 32, 33 Moreover, we observed that allogeneic recipients were at increased risk of ICU mortality, an expected consequence of treatment-related toxicity owing to the risks associated with immune complications, such as GVHD. After controlling for other variables considered in our model, a diagnosis of sepsis predicted lower ICU mortality, underscoring the treatable nature of sepsis after early and aggressive intervention. 34 One recent study of patients undergoing autologous transplantation found sepsis to be associated with increased mortality, 6 although their population of patients included a proportion with AL amyloidosis in which complications associated with sepsis may be more difficult to manage.
In addition to clinical service, the RACE team provides outreach education and clinical training for housestaff and nursing staff during in-hospital medical emergencies. The skills taught by RACE to hematology-based nurses and junior staff could be transferable to the management of all ward-based patients, resulting in global improvements in the stabilization of all patients on the ward, on admission from the emergency department, awaiting RACE assessment or pending ICU transfer.
There were several limitations to our study worth acknowledging. The before-and-after study design may be associated with inherent bias due to the retrospective nature of data retrieval. Relatively small sample sizes associated with the ICU and allogeneic cohorts reduced the potential power of our study, limiting the ability to detect small but clinically relevant differences in patient outcomes. Concomitant innovations in the care of HSCT patients could have influenced our observations. Advancements in ICU care such as early goal-directed therapy, activated protein C therapy, lung protective and ventilation strategies could have contributed to improved outcomes of patients admitted to ICU. An obstacle in extrapolating our results to other health care environments is the lack of consistent terminology. A review of the literature fails to demonstrate any type of consensus on how to describe existing CCO models. Although general consensus on the fundamental framework has been achieved, several variations currently exist for CCO teams. Some have adopted a physician-led format, whereas others are run entirely by nurses; CCO trigger systems vary between institutions; the service is often only available during day-time hours, while others function 24-h a day; CCO capabilities vary from hospital-to-hospital, providing post-ICU discharge follow-up in some cases and not others. Most previous studies have not specified these parameters, thus slowing the process of standardization that seems crucial for allowing more objective comparisons. 17 In conclusion, the introduction of RACE may contribute to earlier stabilization of HSCT recipients experiencing serious transplant-related complications and may be most relevant in the allogeneic transplant setting. Although there was no appreciable difference in mortality observed in our study, further research is required in larger populations of HSCT patients to better define the full impact of CCO on HSCT recipients.
